MET and neoplasm: For the phase Ib part, the patient selection criteria were either MET GCN ≥ 5 and/or a MET/CEP7 ratio ≥ 2.0 or MET overexpression as IHC2+ or IHC3+ in ≥ 50% of the tumor cells.